JP2022546807A5 - - Google Patents

Info

Publication number
JP2022546807A5
JP2022546807A5 JP2022513249A JP2022513249A JP2022546807A5 JP 2022546807 A5 JP2022546807 A5 JP 2022546807A5 JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022546807 A5 JP2022546807 A5 JP 2022546807A5
Authority
JP
Japan
Prior art keywords
group
independently
aliphatic
formula
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022513249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546807A (ja
JP7862297B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050936 external-priority patent/WO2021042174A1/en
Publication of JP2022546807A publication Critical patent/JP2022546807A/ja
Publication of JP2022546807A5 publication Critical patent/JP2022546807A5/ja
Application granted granted Critical
Publication of JP7862297B2 publication Critical patent/JP7862297B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513249A 2019-09-04 2020-09-04 癌の治療 Active JP7862297B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903263 2019-09-04
AU2019903263A AU2019903263A0 (en) 2019-09-04 Cancer treatment
AU2019904863A AU2019904863A0 (en) 2019-12-20 Cancer treatment (2)
AU2019904863 2019-12-20
PCT/AU2020/050936 WO2021042174A1 (en) 2019-09-04 2020-09-04 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078263A Division JP2026129928A (ja) 2019-09-04 2026-05-07 癌の治療

Publications (3)

Publication Number Publication Date
JP2022546807A JP2022546807A (ja) 2022-11-09
JP2022546807A5 true JP2022546807A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7862297B2 JP7862297B2 (ja) 2026-05-19

Family

ID=74851931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513249A Active JP7862297B2 (ja) 2019-09-04 2020-09-04 癌の治療

Country Status (5)

Country Link
US (1) US20220347146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025203A4 (cg-RX-API-DMAC7.html)
JP (1) JP7862297B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020343725B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021042174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861426A4 (en) * 2005-02-08 2008-11-12 Queensland Inst Med Res IMMUNOGENOUS MOLECULES
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
CA2811957C (en) * 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IN2014CN02581A (cg-RX-API-DMAC7.html) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
AU2018241248B2 (en) * 2017-03-31 2025-01-23 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
IL275360B2 (en) * 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
JP2022546806A (ja) * 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌免疫療法

Similar Documents

Publication Publication Date Title
JP2025160318A5 (cg-RX-API-DMAC7.html)
JP2025160317A5 (cg-RX-API-DMAC7.html)
TWI250163B (en) Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
JP2022546806A5 (cg-RX-API-DMAC7.html)
JP2024522174A5 (cg-RX-API-DMAC7.html)
JP2023520047A5 (cg-RX-API-DMAC7.html)
JP2019043957A5 (cg-RX-API-DMAC7.html)
JP2021152063A5 (cg-RX-API-DMAC7.html)
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2020508985A5 (cg-RX-API-DMAC7.html)
JP2011524422A5 (cg-RX-API-DMAC7.html)
CN102317257A (zh) 制备不对称双(缩氨基硫脲)的方法
TW442452B (en) Serine protease inhibitors having an alkynylamino side chain
JP2015512413A5 (cg-RX-API-DMAC7.html)
JP2022541747A5 (cg-RX-API-DMAC7.html)
TW201609745A (zh) 抗病毒化合物的固態形式
JP2024510939A5 (cg-RX-API-DMAC7.html)
JP2023538524A5 (cg-RX-API-DMAC7.html)
JP2022539091A5 (cg-RX-API-DMAC7.html)
JP2017518363A5 (cg-RX-API-DMAC7.html)
JP2023552490A5 (cg-RX-API-DMAC7.html)
JP2023554391A5 (cg-RX-API-DMAC7.html)
HU195830B (en) Process for preparing tumor inhibiting (1-benzyl-ethylene-diamine)-platinum(ii) complexes and pharmaceutical compositions containing such compounds
JP2005501121A5 (cg-RX-API-DMAC7.html)